MALVERN, Pa.--(BUSINESS WIRE)--TetraLogic Pharmaceuticals today announced that the Japan Patent Office (JPO) issued a Decision to Grant the company a patent that claims birinapant, a Smac mimetic currently in Phase 2 clinical studies for the treatment of various cancers. The allowed Japanese patent application, JP 2007-557249, has claims directed to the class of Smac mimetics that encompasses birinapant as a new chemical entity (NCE) and to drug products comprising birinapant and structurally related Smac mimetics. A Decision to Grant is issued after the JPO makes a determination that a patent can be granted from an application. The issued patent would have a term that expires no earlier than in 2026.
